How should I evaluate and manage a patient with elevated cortisol levels?

Evaluation and Management of Elevated Cortisol Levels

Begin by confirming true hypercortisolism using at least two different screening tests—24-hour urinary free cortisol, late-night salivary cortisol (measured on 2-3 occasions), or 1-mg overnight dexamethasone suppression test—then determine ACTH-dependency to classify the etiology and guide treatment urgency based on disease severity. 1, 2

Initial Diagnostic Workup

Rule Out Exogenous Causes First

• Exclude exogenous glucocorticoid use (including inhaled fluticasone, topical steroids, or oral contraceptives) as this is the most common cause of elevated cortisol 1, 2
• Ensure a 2-week washout period from any exogenous steroids before interpreting biochemical tests 2

Confirm Hypercortisolism with Multiple Tests

• Obtain at least two of the following screening tests to confirm autonomous cortisol production 1, 2:
  • 24-hour urinary free cortisol (UFC) on 2-3 separate collections—values above the upper limit of normal suggest Cushing's syndrome, though this has the lowest sensitivity 2
  • Late-night salivary cortisol measured on 2-3 occasions between 23:00-01:00h—values above the upper limit of normal indicate loss of circadian rhythm with 92% sensitivity 2, 3
  • 1-mg overnight dexamethasone suppression test—post-dexamethasone cortisol >50 nmol/L (>1.8 μg/dL) is concerning for Cushing's syndrome 2
  • Midnight serum cortisol ≥50 nmol/L (≥1.8 μg/dL) has 100% sensitivity, particularly useful in pediatric populations 2

Critical pitfall: A single normal test does NOT exclude Cushing's syndrome—episodic hypercortisolism is highly prevalent in mild disease, with 92% of confirmed Cushing's patients having at least one normal test result 4. Multiple sequential measurements over weeks to months may be required to capture episodic cortisol excess 2, 4.

Determine ACTH-Dependency

• Measure 09:00h plasma ACTH once hypercortisolism is confirmed to differentiate ACTH-dependent (pituitary or ectopic) from ACTH-independent (adrenal) causes 2
• This classification is crucial as it fundamentally changes the treatment approach 1

Identify Pseudo-Cushing's States

• Consider physiologic hypercortisolism in patients with depression, alcoholism, or severe obesity—these conditions can mimic Cushing's syndrome 2
• Manage the underlying condition, monitor for 3-6 months, and repeat testing after appropriate washout periods 2

Assess Disease Severity and Clinical Impact

Evaluate for Overt Cushing's Syndrome Features

• Look for classic Cushingoid features: plethora, purple striae (>1 cm wide), proximal muscle weakness, moon facies, supraclavicular fat pads, easy bruising 5, 6
• Important caveat: Many patients with adrenal adenomas causing hypercortisolism do NOT present with overt Cushingoid features but still suffer significant morbidity 6

Screen for Hypercortisolism-Related Comorbidities

• Metabolic complications: Type 2 diabetes, impaired glucose tolerance, hypertension, dyslipidemia, central obesity 5, 6, 7
• Skeletal complications: Osteoporosis and vertebral fractures 6, 7
• Cardiovascular risk: Increased cardiovascular events and mortality 6
• Electrolyte abnormalities: Hypokalemia (particularly with severe disease) 5

Classify Disease Severity

• Mild disease: Subtle clinical features, no visible tumor on MRI, mild biochemical elevations 1
• Moderate disease: Visible tumor with progressive metabolic comorbidities 1
• Severe disease: Life-threatening complications requiring rapid cortisol normalization 1

Management Strategy Based on Etiology and Severity

For Adrenal Causes (ACTH-Independent)

Overt Cushing's Syndrome from Unilateral Adrenal Lesion

• Perform unilateral adrenalectomy of the affected gland using minimally invasive surgery when feasible 5
• This is the definitive treatment for patients with clinically apparent Cushing's syndrome 5

Mild Autonomous Cortisol Secretion (MACS)

• For younger patients with MACS and progressive metabolic comorbidities attributable to cortisol excess, consider adrenalectomy after shared decision-making 5
• Post-dexamethasone cortisol >50 nmol/L but <138 nmol/L (>1.8 but <5 μg/dL) with metabolic complications defines this population 5, 2
• For patients not managed surgically, perform annual clinical screening for new or worsening comorbidities 5
• Key evidence: MACS is associated with type 2 diabetes, hypertension, cardiovascular events, vertebral fractures, and mortality, but does NOT progress to overt Cushing's syndrome 5

For Cushing's Disease (ACTH-Dependent, Pituitary Origin)

Mild Disease Without Visible Tumor

• First-line medical therapy: ketoconazole, osilodrostat, or metyrapone 1
• Alternative for mild disease: cabergoline (25-40% biochemical normalization, but only 23% sustained control at median 32.5 months) 5, 1
• Avoid cabergoline in patients with history of bipolar disorder or impulse-control disorders (can manifest as hypersexuality, pathological gambling, excessive alcohol consumption) 5, 1

Moderate Disease With Visible Tumor

• Consider medications with tumor-shrinking potential: cabergoline or pasireotide 1
• Critical warning for pasireotide: Approximately 70% of patients develop hyperglycemia-related adverse events, requiring new antidiabetic medication or dose adjustments in ~50% 5
• Manage pasireotide-induced hyperglycemia with GLP-1 receptor agonists or DPP-4 inhibitors (preferred due to mechanism of action) 5

Severe Disease Requiring Rapid Cortisol Normalization

• First-line options: osilodrostat, metyrapone, ketoconazole, or etomidate 1
• Consider combination therapy with multiple steroidogenesis inhibitors when monotherapy is insufficient 1
• Rational combination: ketoconazole plus metyrapone to maximize adrenal blockade 1
• Alternative combination: steroidogenesis inhibitor plus tumor-targeting agent when visible tumor is present 1

Glucocorticoid Receptor Blockade with Mifepristone

• Mifepristone is effective for controlling metabolic effects of hypercortisolism regardless of etiology 5
• After 24 weeks: 60% of patients with diabetes/impaired glucose tolerance showed ≥25% reduction in glucose AUC; 38% with hypertension showed ≥5 mmHg diastolic BP reduction 5
• Critical monitoring caveat: Cortisol levels remain high with mifepristone—you CANNOT use cortisol measurements for dosing or safety monitoring; only clinical features can assess adrenal insufficiency 5, 1
• Adverse effects: Hypokalemia requiring spironolactone (9 patients), endometrial hypertrophy, irregular menstrual bleeding, potential tumor progression in macroadenomas 5
• Monitor thyroid function closely and adjust thyroid hormone replacement as needed 5
• Review all concomitant medications for drug-drug interactions 5, 1

Osilodrostat-Specific Dosing and Monitoring (FDA-Approved)

• Correct hypokalemia and hypomagnesemia BEFORE starting osilodrostat 8
• Obtain baseline ECG and repeat within one week after treatment initiation 8
• Starting dose: 2 mg orally twice daily (with or without food) 8
• Titration schedule: Increase by 1-2 mg twice daily every 2 weeks based on cortisol changes and tolerability 8
• If patient tolerates 10 mg twice daily but UFC remains elevated: Increase by 5 mg twice daily every 2 weeks 8
• Maximum maintenance dose: 30 mg twice daily 8
• Monitor UFC from at least two 24-hour collections every 1-2 weeks until adequate response, then every 1-2 months 8

Dose modifications for hepatic impairment: 8

• Moderate impairment (Child-Pugh B): Start at 1 mg twice daily
• Severe impairment (Child-Pugh C): Start at 1 mg once daily in evening
• More frequent monitoring required during titration

Warning for hypocortisolism: Osilodrostat can cause life-threatening adrenal insufficiency—watch for nausea, vomiting, fatigue, abdominal pain, loss of appetite, dizziness, hypotension, electrolyte abnormalities, and hypoglycemia 8

Monitoring Treatment Response

Biochemical Monitoring

• Use multiple serial tests of both urinary free cortisol AND late-night salivary cortisol to monitor treatment outcomes 1
• In patients with moderate-to-severe renal impairment, use caution interpreting UFC levels due to reduced excretion 8
• Repeat testing every 1-2 weeks during titration, then every 1-2 months once maintenance dose achieved 1, 8

Assess for Hypocortisolism/Adrenal Insufficiency

• Decrease or temporarily discontinue therapy if: 8
  • UFC falls below target range
  • Rapid decrease in cortisol levels occurs
  • Patient reports symptoms of hypocortisolism (nausea, vomiting, fatigue, abdominal pain, hypotension)
• Stop treatment and administer exogenous glucocorticoid replacement if serum/plasma cortisol is below target AND patient has symptoms of adrenal insufficiency 8
• Re-initiate at lower dose when cortisol levels normalize and symptoms resolve 8

Monitor for Comorbidity Improvement

• Track improvement in weight, glycemic control, blood pressure, bone density, and quality of life 5
• For patients with slight biochemical abnormalities without clinical features, close monitoring with repeat testing and treatment of comorbidities may be preferred over treating the underlying disorder 1

Special Populations

Pregnancy Considerations

• Women desiring pregnancy may prefer cabergoline (used safely in prolactinomas during pregnancy) 5, 1
• Metyrapone may be considered with precautions in selected pregnant women 1

Night-Shift Workers

• Do not use late-night cortisol testing due to disrupted circadian rhythm 2

Patients with Cyclic Cushing's Syndrome

• Require multiple sequential late-night measurements over weeks to months to capture episodic cortisol excess 2

Key Pitfalls to Avoid

• Not considering disease severity when selecting initial therapy—severe disease requires rapid-acting agents like osilodrostat or metyrapone 1
• Failing to monitor for drug-drug interactions, particularly with ketoconazole and mifepristone 1
• Using cortisol measurements to guide mifepristone dosing—this is unreliable and dangerous 5, 1
• Assuming a single normal cortisol test excludes Cushing's syndrome—episodic hypercortisolism requires multiple tests 4
• Ignoring false elevations from increased cortisol-binding globulin (pregnancy, oral estrogens, chronic hepatitis) or false decreases (nephrotic syndrome, malnutrition) 2
• Not accounting for CYP3A4 inducers that accelerate dexamethasone metabolism, causing false-positive suppression tests 2